Hypoglycaemia in elderly patients with diabetes mellitus: Causes and strategies for prevention

Drugs and Aging

Volumn 21, Issue 8, 2004, Pages 511-530

  Chelliah, Aruna ^a   Burge, Mark R ^a  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETOHEXAMIDE; ADRENALIN; ALCOHOL; ALLOPURINOL; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CHLORAMPHENICOL; CHLORPROPAMIDE; CLOFIBRATE; DICOUMAROL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLIBENCLAMIDE; GLIPIZIDE; GLUCAGON; GLUCOSE; GROWTH HORMONE; GUANETHIDINE; HYDROCORTISONE; INSULIN; MONOAMINE OXIDASE INHIBITOR; PHENYLBUTAZONE; PROBENECID; SALICYLIC ACID; SULFAPHENAZOLE; SULFONAMIDE; SULFONYLUREA; TOLAZAMIDE; TOLBUTAMIDE; UNINDEXED DRUG; WARFARIN;

AGE DISTRIBUTION; AGED; AUTOREGULATION; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DISEASE CLASSIFICATION; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG CLEARANCE; DRUG COST; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG METABOLISM; DRUG TOLERABILITY; ECONOMIC ASPECT; ELDERLY CARE; EMOTIONAL STRESS; EVALUATION; EXERCISE; FAMILY; GLUCOSE BLOOD LEVEL; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HEALTH CARE COST; HEALTH CARE PERSONNEL; HOSPITALIZATION; HUMAN; HYPOGLYCEMIA; KIDNEY FUNCTION; MEDLINE; NURSING HOME; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PATIENT EDUCATION; PHYSICIAN; POLYPHARMACY; PRACTICE GUIDELINE; PREDICTION; PRESCRIPTION; PRIORITY JOURNAL; QUALITY OF LIFE; RECURRENT ABORTION; REGULATORY MECHANISM; REVIEW; RISK FACTOR; SOCIAL PSYCHOLOGY; TREATMENT PLANNING;

ADRENERGIC BETA-ANTAGONISTS; AGED; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; DIABETES COMPLICATIONS; DIABETES MELLITUS; GLUCOSE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; POLYPHARMACY; RISK FACTORS;

EID: 3042823834     PISSN: 1170229X     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002512-200421080-00003     Document Type: Review

References (94)

1. Harris MI. Undiagnosed NIDDM: clinical and public health issues. Diabetes Care 1993; 16 (4): 642-52
2. Harris MI, Epidemiological correlates of NIDDM in Hispanic, Whites and Blacks in the US population. Diabetes Care 1991; 14 (7): 639-48
3. Rockwood K, Await E, MacKnight C, et al. Incidence and outcomes of diabetes mellitus in elderly people: report from the Canadian study of health and aging. CMAJ 2000; 162 (6): 769-72
4. Teuscher AU, Reinli K, Teuscher A. Prevalence of diabetes mellitus and impaired glucose in elderly European subjects. Diabetes 1999; 48 Suppl. 1: 395-6
5. Bertoni AG, Krop JS, Anderson GF, et al. Diabetes-related morbidity and mortality in a national sample of US elders. Diabetes Care 2002; 25: 471-5
6. Krop JS, Powe NR, Weller WE, et al. Patterns of expenditures and use of services among older adults with diabetes: implications for transition to capitated managed care. Diabetes Care 1998; 21: 747-52
7. Holstein A, Plaschke A, Egberts EH. Incidence and costs of severe hypoglycemia. Diabetes Care 2002; 25: 2109-10
8. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med 1993; 329: 977-86
9. The UKPDS Group. Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-53
10. Cryer PE, Gerich JE. Hypoglycemia in insulin-dependent diabetes mellitus: interplay of insulin excess and compromised glucose counterregulation. In: Porte D, Sherwin RS, editors. Ellenburg and Rifkin's diabetes mellitus: theory and practice. 5th ed. Stamford (CT); Appleton and Lange, 1997: 745-60
11. Herbel G, Boyle PJ. Hypoglycemia: pathophysiology and treatment. Endocrinol Metab Clin N Am 2000; 29: 725-43
12. Pardridge WM. Brain metabolism: a perspective from the blood-brain barrier. Physiol Rev 1983; 63 (4): 1481-535
13. Pardridge WM, Boado RJ, Farrell CR. Brain-type glucose transporter (GLUT-1) is selectively localized to the blood brain barrier: studies with quantitative western blotting and in situ hybridization. J Biol Chem 1990; 265: 18035-40
14. Borg MA, Sherwin RS, Borg WP, et al. Local ventromedial hypothalamus glucose perfusion blocks counterregulation during systemic hypoglycemia in awake rats. J Clin Invest 1997; 99 (2): 361-5
15. Borg WP, During MJ, Sherwin RS, et al. Ventromedial hypothalamus lesions in rats suppress counterregulatory hormone responses to hypoglycemia. J Clin Invest 1994; 93 (4): 1677-82
16. Borg WP, Sherwin RS, During MJ, et al. Local ventromedial hypothalamus glycopenia triggers counterregulatory hormone release. Diabetes 1995; 44 (2): 180-4
17. Cryer PE. Glucose counterregulation: prevention and correction of hypoglycemia in humans. Am J Physiol 1993; 264 (2 Pt 1): E149-55
18. Rizza RA, Mandarino LJ, Gerich JE. Dose-response characteristics for the effects of insulin on production and utilization of glucose in man. Am J Physiol 1981; 240: E630-9
19. Schwartz NS, Clutter WE, Shah SD, et al. Glycemic thresholds for activation of glucose counterregulatory systems are higher than the threshold for symptoms. J Clin Invest 1987; 79: 777-81
20. Heller SR, Cryer PE. Hypoinsulinemia is not critical to glucose recovery from hypoglycemia in humans. Am J Physiol 1991; 261: E41-8
21. Gerich J, Davis J, Lorenzi M, et al. Hormonal mechanisms of recovery from insulin induced hypoglycemia in man. Am J Physiol 1979; 236: E380-5
22. Rizza R, Cryer PE, Gerich JE. Role of glucagon, epinephrine and growth hormone in human glucose counterregulation: effects of somatostatin and adrenergic blockade on plasma glucose recovery and glucose flux rates following insulin induced hypoglycemia. J Clin Invest 1979; 64: 62-71
23. Rizza RA, Cryer PE, Haymond MW, et al. Adrenergic mechanisms for the effect of epinephrine on glucose production and clearance in man. J Clin Invest 1980; 65: 682-9
24. Rizza RA, Cryer PE, Haymond MW, et al. Differential effects of physiological concentration of epinephrine on glucose production and disposal in man. Am J Physiol 1979; 237: E356-62
25. White NH, Skor DA, Cryer PE, et al. Identification of type 1 diabetic patients at increased risk for hypoglycemia during intensive therapy. N Engl J Med 1983; 308: 485-91
26. Bolli GB, DeFeo P, DeCosmo S, et al. A reliable and reproducible test for adequate glucose counterregulation in type 1 diabetes mellitus. J Clin Invest 1985; 75: 1623-31
27. Caprio S, Gelfand RA, Tamborlane WV, et al. Oxidative fuel metabolism during mild hypoglycemia: critical role of free fatty acids. Am J Physiol Endocrinol Metab 1989; 256: E413-9
28. Fanelli CG, De Feo P, Porcellati F, et al. Adrenergic mechanisms contribute to the late phase of hypoglycemic glucose counterregulation in humans by stimulating lipolysis. Clin Invest 1992; 89 (6): 2005-13
29. Boyle PJ, Cryer PE. Growth hormone, cortisol, or both are involved in defense against, but are not critical to recovery from, hypoglycemia. Am J Physiol 1991; 260: E395-402
30. Mitrakou A, Ryan C, Veneman T, et al. Hierarchy of glycemic thresholds for counterregulatory hormone secretion, symptoms, and cerebral dysfunction. Am J Physiol 1991; 260: E67-74
31. Bolli GB, DeFeo P, Perriello G, et al. Role of hepatic autoregulation in defense against hypoglycemia in humans. J Clin Invest 1985; 75: 1623-31
32. Hansen I, Firth R, Haymond M, et al. The role of autoregulation of hepatic glucose production in man: response to a physiologic decrements in plasma glucose. Diabetes 1986; 35: 186-91
33. Campbell PJ, Bolli GB, Cryer PE, et al. Pathogenesis of the dawn phenomenon in patients with insulin-dependent diabetes mellitus: accelerated glucose production and impaired glucose utilization due to nocturnal surges in growth hormone secretion. N Engl J Med 1985; 312 (23): 1473-9
34. Somogyi M. Insulin as a cause of extreme hyperglycemia and instability. Bull St Louis Med Soc 1938; 32: 498-501
35. Bolli GB, Gottesman IS, Campbell PJ, et al. Glucose counter-regulation and waning of insulin in the Somogyi phenomenon (posthypoglycemic hyperglycemia). N Engl J Med 1984; 311 (19): 1214-9
36. Kollind M. Studies on posthypoglycemic insulin resistance in insulin-dependent diabetes mellitus. Acta Med Scand Suppl 1988; 727: 1-56
37. Shorr RI, Ray WA, Daugherty JR, et al. Incidence and risk factors for serious hypoglycemia in older persons using insulin or sulfonylureas. Arch Intern Med 1997; 157: 1681-6
38. Zimmerman BR. Sulfonylureas. Endocrinol Metab Clin North Am 1997; 26: 511-22
39. Seltzer HS. Drug-induced hypoglycemia: a review of 1418 cases. Endocrinol Metab Clin North Am 1989; 18: 163-83
40. Casparie AF, Elving LD. Severe hypoglycemia in diabetic patients: frequency, causes, prevention. Diabetes Care 1985; 8: 141-5
41. Fertig BJ, Simmons DA, Martin DB. Therapy for diabetes. In: Harris MI, Cowie CC, Stern MP, et al., editors. Diabetes in America. 2nd ed. Bethesda (MD): DHHS (NIH), 1995; Publication no. 95-1468: 519-40
42. Gerich JE. Oral hypoglycemic agents. N Engl J Med 1989; 321: 1231-41
43. Wiholm BE, Westerholm B. Drug utilization and morbidity statistics for the evaluation of drug safety in Sweden. Acta Med Scand Suppl 1984; 683: 107-17
44. Berger W. Incidence of severe side effects during therapy with sulfonylureas and biguanides. Hormone Metab Res 1985; 17 Suppl. 15: 111-5
45. Campbell IW. Metformin and the sulfonylureas: the comparative risk. Horm Metab Res 1985; 17 Suppl. 15: 105-11
46. Van Staa T, Abenhaim L, Monette J. Rates of hypoglycemia in users of sulfonylureas. J Clin Epidemiol 1997; 50: 735-41
47. Shorr RI, Ray WA, Daugherty JR, et al. Individual sulfonylureas and serious hypoglycemia in older people. J Am Geriatr Soc 1996; 44: 751-5
48. Stahl M, Berger W. Higher incidence of severe hypoglycemia leading to hospital admission in type 2 diabetic patients treated with long-acting versus short-acting sulfonylureas. Diabet Med 1999; 16: 586-90
49. Jennings AM, Wilson RM, Ward JD. Symptomatic hypoglycaemia in NIDDM patients treated with oral hypoglycaemic agents. Diabetes Care 1989; 12: 203-8
50. Burge MR, Schmitz-Fiorentino K, Fischette C, et al. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. JAMA 1998; 279: 137-43
51. Walter MW. Hypoglycemia: still a risk in the elderly. Geriatrics 1990; 45: 69-75
52. Brodows RG. Benefits and risks with glyburide and glipizide in elderly NIDDM patients. Diabetes Care 1992; 15: 75-80
53. Heinsmer JA, Lefowitz RJ. The impact of aging and adrenergic receptor function: clinical and biochemical aspects. J Am Geriatr Soc 1985; 33: 184-8
54. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type a diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998; 317: 713-20
55. Shorr RI, Wayne AR, Daugherty JR, et al. Antihypertensives and the risk of serious hypoglycemia in older persons using insulin or sulfonylureas. JAMA 1997; 278: 40-3
56. Herings RM, de Boer A, Stricker BH, et al. Hypoglycemia associated with use of inhibitors of angiotensin-converting enzymes. Lancet 1995; 345: 1195-8
57. Rasmussen BM, Orskov L, Schmitz O, et al. Alcohol and glucose counterregulation during acute insulin induced hypoglycemia in type 2 diabetes subjects. Metabolism 2001; 50: 451-7
58. Burge MR, Zeise TM, Sobhy TA, et al. Low dose ethanol predisposes elderly fasted patients with type 2 diabetes to sulfonylurea-induced low blood glucose. Diabetes Care 1999; 22: 2037-43
59. Sood V, Sobhy TA, Schade DS, et al. Low dose ethanol delays recovery from hypoglycemia in type 2 diabetes [abstract]. Diabetes 2000; 49 Suppl. 1: A66
60. Sood V, Sobhy T, Schade DS, et al. Low dose ethanol alters epinephrine responses and decreases glucose production during hypoglycemia in patients with type 2 diabetes [abstract]. Diabetes 2001; 50 Suppl. 1: A139
61. Riddle MC, McDaniel PA, Tive LA. Glipizide GITS does not increase the hypoglycemic effect of mild exercise during fasting in NIDDM. Diabetes Care 1997; 20: 992-4
62. Katz MS, Lowenthal DT. Influences of age and exercise on glucose metabolism: implications for management of older diabetics. South Med J 1994; 87: S70-3
63. Gerich JE, Langlois M, Noacco C, et al. Lack of glucagon response to hypoglycemia in diabetes: evidence for an intrinsic pancreatic alpha cell defect. Science 1973; 182: 171-3
64. Fukuda M, Tanaka A, Tahara Y, et al. Correlation between minimal secretory capacity of pancreatic beta-cells and stability of diabetic control. Diabetes 1988; 37: 81-8
65. Robertson RP, Porte Jr D. The glucose receptor: a defective mechanism in diabetes mellitus distinct from the beta-adrenergic receptor. J Clin Invest 1973; 52: 870-6
66. Meneilly GS, Cheung E, Tuokko H. Altered response to hypoglycemia of healthy elderly people. J Clin Endocrinol Metab 1994; 78: 1341-8
67. Marker JC, Cryer PE, Clutter WE. Attenuated glucose recovery from hypoglycemia in the elderly. Diabetes 1992; 41: 671-8
68. Meneilly GS, Cheung E, Tuokko H. Counterregulatory hormone responses to hypoglycemia in the elderly patient with diabetes. Diabetes 1994; 43: 403-10
69. Segel SA, Deanna SP, Paramore S, et al. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51: 724-33
70. Korzon-Burakowska A, Hopkins D, Matyka K, et al. Effects of glycemic control on protective responses against hypoglycemia in type 2 diabetes. Diabetes Care 1998; 21: 283-90
71. Burge MR, Sobhy TA, Qualls CR, et al. Effect of short-term glucose control on glycemic thresholds for epinephrine and hypoglycemice symptoms. J Clin Endocrinol Metab 2001; 86: 5471-8
72. Mokan M, Mitrakou A, Veneman T, et al. Hypoglycemia unawareness in IDDM. Diabetes Care 1994; 17: 1397-403
73. Gold AE, MacLeod KM, Frier BM. Frequency of severe hypoglycemia in patients with type I diabetes with impaired awareness of hypoglycemia. Diabetes Care 1994; 17: 697-703
74. Veneman T, Mitrakou A, Mokan M, et al. Induction of hypoglycemia unawareness by symptomatic nocturnal hypoglycemia. Diabetes 1993; 42: 1233-7
75. Thomson FJ, Masson EA, Leeming JT, et al. Lack of knowledge of symptoms of hypoglycemia by elderly diabetic patients. Age Ageing 1991; 20: 404-6
76. Schillinger D, Grumbach K, Piette J, et al. Association of health literacy with diabetes mellitus. JAMA 2002; 288: 475-82
77. Colleran KM, Starr B, Burge MR. Putting diabetes to the test: analyzing glycemic control based on patients' diabetes knowledge. Diabetes Care 2003; 26: 2220-1
78. Rabasa-Lhoret R, Bourque J, Ducros F, et al. Guidelines for premeal insulin dose reduction for postprandial exercise of different intensities and durations in type 1 diabetic subjects treated intensively with a basal-bolus insulin regimen (ultralente-lispro). Diabetes Care 2001; 24 (4): 625-30
79. Rosenstock J, Shen GS, Gatlin MR, et al. Combination therapy with nateglinide and a thiazolidinedione improves glycemic control in type 2 diabetes. Diabetes Care 2002; 25: 1529-33
80. Saloranta C, Kenneth H, Ball M, et al. Efficacy and safety of nateglinide in type 2 diabetic patients with modest fasting hyperglycemia. J Clin Endocrinol Metab 2002; 87: 4171-6
81. Frische A, Schweitzer MA, Häring HU, et al. Glimepiride combined with morning insulin glargine, bedtime neutral protamine hagedorn insulin, or bedtime insulin glargine in patients with type 2 diabetes. Ann Intern Med 2003; 138: 952-9
82. Yki-Jarvinen H, Dressler A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bed-time insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000; 23: 1130-6
83. Cooper WC. Fatal asymptomatic hypoglycemia in an elderly insulin-dependent diabetic patient taking an oral beta-blocking medication. Diabetes Care 1998; 21: 2197-8
84. Fischer KF, Lees JA, Newman JH. Hypoglycemia in hospitalized patients. N Engl J Med 1986; 315: 1245-50
85. Benbow SJ, Walsh A, Gill GV. Diabetes in the institutionalised elderly: a forgotten population? BMJ 1997; 315: 1868-70
86. Tattersall R, Simon P. Managing diabetes in residential and nursing homes: presents a complex set of problems with no one solution. BMJ 1998; 316: 89
87. Effects of intensive diabetes therapy on neuropsychological function in adults in the diabetes control and complications trial. Ann Intern Med 1996; 124: 379-88
88. Pramming S, Thorsteinsson B, Theilgaard A, et al. Cognitive function during hypoglycaemia in type I diabetes mellitus. BMJ 1986; 292: 647-50
89. Fontbonne A, Berr C, Ducimetiere P. Poorer cognitive performance evolution over four years in elderly diabetics compared to controls with normal or impaired fasting blood glucose. Diabetes 2000; 49 Suppl. 1: A191-2
90. Davis SN, Shavers C, Davis B, et al. Prevention of an increase in plasma cortisol during hypoglycemia preserves subsequent counterregulatory responses. J Clin Invest 1997; 100: 429-38
91. Dagogo-Jack S, Rattarasarn C, Cryer PE. Reversal of hypoglycemia unawareness, but not defective glucose counterregulation, in IDDM. Diabetes 1994; 43: 1426-34
92. Cranston I, Lomas J, Maran A, et al. Restoration of hypoglycaemia awareness in patients with long-duration insulin-dependent diabetes. Lancet 1994; 344: 283-7
93. Shichiri M, Kishikawa H, Ohkubo Y, et al. Long-term results of the Kumamoto study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000; 23 Suppl. 2: B21-9
94. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes: technical review. Diabetes Care 2003; 26: 1902-12